Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
A phase 2 trial of Nivolumab in non-small-cell lung cancer and small-cell lung cancer, run by Replimune, Inc., active and no longer recruiting.
Overview
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) is a phase 2 interventional study registered as NCT03767348 by Replimune, Inc., with 340 participants planned, started 2017-09-20 and due to reach its primary completion in 2028-06. Interventions recorded: RP1, nivolumab. Conditions listed: Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult P
- TrialA Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Shares Nivolumab, Melanoma, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
Shares Nivolumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Ca
Shares Nivolumab, Melanoma, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
Shares Skin cancer (all types), Melanoma.
- TrialA Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Rese
Shares Nivolumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialEffectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
- TrialA Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma